HRP20210399T1 - Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) - Google Patents

Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) Download PDF

Info

Publication number
HRP20210399T1
HRP20210399T1 HRP20210399TT HRP20210399T HRP20210399T1 HR P20210399 T1 HRP20210399 T1 HR P20210399T1 HR P20210399T T HRP20210399T T HR P20210399TT HR P20210399 T HRP20210399 T HR P20210399T HR P20210399 T1 HRP20210399 T1 HR P20210399T1
Authority
HR
Croatia
Prior art keywords
antibody
antigen
binding portion
use according
hpv
Prior art date
Application number
HRP20210399TT
Other languages
English (en)
Inventor
Demetrios MANEKAS
Joseph GROSSO
Jeffrey Anderson
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56551000&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20210399(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20210399T1 publication Critical patent/HRP20210399T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/708—Specific hybridization probes for papilloma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)

Claims (17)

1. Antitijelo ili njegov dio koji se vezuje za antigen, koji se specifično vezuje za receptor programirane smrti-1 (PD-1) ili ligand programirane smrti-1 (PD-L1) i inhibira PD-1 aktivnost za primjenu u postupku liječenja subjekta koji je pogođen tumorom izvedenim iz raka glave i vrata karcinoma skvamoznih stanica (SCCHN) pozitivnog na humani papiloma virus (HPV) koji obuhvaća administriranje subjektu terapijski efikasne količine antitijela ili njegovog dijela koji veže antigen, pri čemu je subjekt identificiran kao HPV pozitivan.
2. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 1, pri čemu HPV-pozitivni SCCHN obuhvaća tumor koji eksprimira jedan ili više proteina izvedenih iz HPV ili obuhvaća nukleotidnu sekvencu koja kodira jedan ili više proteina.
3. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 2, pri čemu jedan ili više proteina izvedenih iz HPV obuhvaćaju p16, Ki-67, ciklin D1, p53, ProEx C, E6, E7, ili bilo koju njihovu kombinaciju.
4. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu HPV obuhvaća HPV podtip 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, ili bilo koju njihovu kombinaciju.
5. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu više od oko 70% tumorskih stanica pokazuje snažno i difuzno nuklearno i citoplazmatsko bojenje imunohistokemijom protiv p16.
6. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu tumor dalje eksprimira PD-L1.
7. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu antitijelo je kimerno, humanizirano ili humano monoklonsko antitijelo ili njegov dio.
8. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu antitijelo obuhvaća konstantnu regiju teškog lanca koji je od humanog IgG1 ili IgG4 izotipa.
9. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu antitijelo je nivolumab ili pembrolizumab.
10. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 9, pri čemu antitijelo se administrira u dozi od najmanje oko 3 mg/kg tjelesne težine ili 240 mg jednom na svaka 2 tjedna.
11. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu antitijelo specifično vezuje PD-L1.
12. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 11, pri čemu antitijelo je odabrano iz grupe koja se sastoji od MPDL3280A, durvalumaba, i avelumaba.
13. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 12, pri čemu postupak dalje obuhvaća administriranje jednog ili više dodatnih agenasa protiv raka.
14. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 13, pri čemu agens protiv raka je odabran iz grupe koja se sastoji od antitijela ili njegovog dijela koji se vezuje za antigen, koji se specifično vezuje za CTLA-4 i inhibira CTLA-4 aktivnost, kemoterapije, dvostruke kemoterapije na bazi platine, inhibitora tirozin kinaze, anti-VEGF inhibitora, ili bilo koje njihove kombinacije.
15. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema bilo kojem od patentnih zahtjeva 1 do 14, pri čemu subjekt je primio jedan ili više agenasa protiv raka prije administriranja antitijela.
16. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 15, pri čemu jedan ili više agenasa protiv raka nisu bili efikasni u liječenju tumora.
17. Antitijelo ili njegov dio koji se vezuje za antigen za primjenu prema patentnom zahtjevu 16, pri čemu jedan ili više agenasa protiv raka obuhvaćaju terapiju na bazi platine.
HRP20210399TT 2015-07-14 2021-03-08 Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) HRP20210399T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192396P 2015-07-14 2015-07-14
EP16744626.9A EP3322731B1 (en) 2015-07-14 2016-07-14 Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
PCT/US2016/042297 WO2017011666A1 (en) 2015-07-14 2016-07-14 Method of treating cancer using immune checkpoint inhibitor

Publications (1)

Publication Number Publication Date
HRP20210399T1 true HRP20210399T1 (hr) 2021-04-30

Family

ID=56551000

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210399TT HRP20210399T1 (hr) 2015-07-14 2021-03-08 Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)

Country Status (16)

Country Link
US (3) US10544224B2 (hr)
EP (2) EP3858859A1 (hr)
JP (2) JP2018522887A (hr)
KR (1) KR20180027576A (hr)
CN (1) CN107922502A (hr)
CY (1) CY1123993T1 (hr)
DK (1) DK3322731T3 (hr)
ES (1) ES2855798T3 (hr)
HR (1) HRP20210399T1 (hr)
HU (1) HUE053966T2 (hr)
LT (1) LT3322731T (hr)
PL (1) PL3322731T3 (hr)
PT (1) PT3322731T (hr)
RS (1) RS61532B1 (hr)
SI (1) SI3322731T1 (hr)
WO (1) WO2017011666A1 (hr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017011644A (es) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anticuerpos anti-pdl1, anticuerpos anti-pdl1 activables y metodos de uso de los mismos.
ES2803655T3 (es) 2015-05-29 2021-01-28 Agenus Inc Aticuerpos anti-ctla-4 y métodos de uso de los mismos
EP3313186A4 (en) 2015-06-29 2019-04-03 Biomed Valley Discoveries, Inc. COMBINATION OF LPT-723 INHIBITORS AND IMMUNE CONTROL POINT AND METHODS OF TREATMENT
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
EP3858859A1 (en) 2015-07-14 2021-08-04 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
EP3334763B1 (en) 2015-08-11 2024-08-07 WuXi Biologics Ireland Limited Novel anti-pd-1 antibodies
CN107949573B (zh) 2015-09-01 2022-05-03 艾吉纳斯公司 抗-pd-1抗体及其使用方法
TWI795347B (zh) * 2015-11-18 2023-03-11 美商必治妥施貴寶公司 使用抗ｐｄ-１抗體與抗ｃｔｌａ-４抗體之組合以治療肺癌
US20200261573A1 (en) * 2015-12-17 2020-08-20 Novartis Ag Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
WO2017157882A1 (en) 2016-03-14 2017-09-21 Université Catholique de Louvain Serine biosynthetic pathway inhibitors
EP3522923A1 (en) * 2016-10-06 2019-08-14 Pfizer Inc Dosing regimen of avelumab for the treatment of cancer
ES2963226T3 (es) 2016-12-07 2024-03-26 Agenus Inc Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos
CN110300599B (zh) 2016-12-07 2024-07-02 艾吉纳斯公司 抗体和其使用方法
NZ759442A (en) 2017-06-01 2024-07-05 Cytomx Therapeutics Inc Activatable anti-pdl1 antibodies, and methods of use thereof
WO2018226529A1 (en) * 2017-06-05 2018-12-13 The Regents Of The University Of Michigan Complexes for delivery of antigenic peptides
KR20200129092A (ko) * 2018-01-12 2020-11-17 그레일, 인코포레이티드. 바이러스 핵산을 분석하기 위한 방법
US20210047409A1 (en) * 2018-02-13 2021-02-18 Merck Sharp & Dohme Corp. Methods for treating cancer with anti pd-1 antibodies and anti ctla4 antibodies
WO2019175328A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4pathwayactivationandusethereoffortreatingcancer
KR20200139724A (ko) * 2018-03-30 2020-12-14 브리스톨-마이어스 스큅 컴퍼니 종양을 치료하는 방법
EP3801501A4 (en) * 2018-06-06 2022-03-23 The Regents of the University of California ESTROGEN RECEPTOR INHIBITORS AND THEIR USES
US20210255168A1 (en) * 2018-06-13 2021-08-19 King Faisal Specialist Hospital & Research Centre A method of precision cancer therapy
JP2022509448A (ja) * 2018-10-31 2022-01-20 ジェネンテック， インコーポレイテッド Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
WO2020156500A1 (zh) * 2019-01-31 2020-08-06 正大天晴药业集团股份有限公司 抗pd-l1抗体治疗头颈癌的用途
KR20220115803A (ko) * 2019-12-13 2022-08-18 삼성바이오에피스 주식회사 안정한 항-pd-1 항체 약제학적 제제
WO2021126906A1 (en) * 2019-12-20 2021-06-24 Merck Sharp & Dohme Corp. Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents
KR102541413B1 (ko) 2020-02-06 2023-06-12 영남대학교 산학협력단 면역 체크포인트 억제제 및 ampk 활성화제를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물
KR20240013352A (ko) 2022-07-22 2024-01-30 가톨릭대학교 산학협력단 디옥시시코닌 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ES2273415T3 (es) 1997-04-07 2007-05-01 Genentech, Inc. Anticuerpos anti-vegf.
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
IL144578A0 (en) 1999-01-29 2002-05-23 Imclone Systems Inc Antibodies specific to kdr and uses thereof
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001054732A1 (en) 2000-01-27 2001-08-02 Genetics Institute, Llc. Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
ES2347543T3 (es) 2002-03-04 2010-11-02 Imclone Llc Anticuerpos humanos especificos para kdr y sus usos.
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
ES2523457T3 (es) 2004-11-18 2014-11-26 Imclone Llc Anticuerpos contra el receptor 1 del factor de crecimiento endotelial vascular
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
EP2397155B1 (en) * 2005-06-08 2017-12-13 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
EP2007423A2 (en) 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
EA034136B1 (ru) 2007-11-09 2020-01-09 Перигрин Фармасьютикалз, Инк. Изолированное антитело, которое связывается с vegf, и его применения
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EA023148B1 (ru) 2008-08-25 2016-04-29 Эмплиммьюн, Инк. Композиции на основе антагонистов pd-1 и их применение
CN114835812A (zh) 2008-12-09 2022-08-02 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
HUE049647T2 (hu) 2009-11-24 2020-09-28 Medimmune Ltd Targetált kötõdõ ágensek B7-H1 ellen
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
SG11201402603WA (en) 2011-11-28 2014-06-27 Merck Patent Gmbh Anti-pd-l1 antibodies and uses thereof
BR112014028826B1 (pt) 2012-05-15 2024-04-30 Bristol-Myers Squibb Company Uso de nivolumab ou pembrolizumabe
BR112015007184A2 (pt) 2012-10-02 2017-08-08 Bristol Myers Squibb Co combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
ES2927567T3 (es) 2013-09-13 2022-11-08 Beigene Switzerland Gmbh Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico
HRP20230603T1 (hr) * 2013-09-20 2023-09-29 Bristol-Myers Squibb Company Kombinacija anti-lag-3 antitijela i anti-pd-1 antitijela za liječenje tumora
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
KR20170007750A (ko) 2014-05-29 2017-01-20 메디뮨 리미티드 Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
US10354541B2 (en) 2014-07-02 2019-07-16 Raytheon Bbn Technologies Corporation Tutor model building system
MA40344A (fr) * 2014-07-18 2016-01-21 Advaxis Inc Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
WO2016029073A2 (en) * 2014-08-22 2016-02-25 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
BR112017021688A2 (pt) * 2015-04-17 2018-08-14 Bristol-Myers Squibb Company composições compreendendo uma combinação de um anticorpo anti-pd-1 e outro anticorpo
EP3858859A1 (en) 2015-07-14 2021-08-04 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)

Also Published As

Publication number Publication date
KR20180027576A (ko) 2018-03-14
EP3322731B1 (en) 2021-01-13
US20240124592A1 (en) 2024-04-18
CY1123993T1 (el) 2022-05-27
LT3322731T (lt) 2021-03-25
RS61532B1 (sr) 2021-04-29
EP3322731A1 (en) 2018-05-23
JP2018522887A (ja) 2018-08-16
DK3322731T3 (da) 2021-03-08
PT3322731T (pt) 2021-02-25
ES2855798T3 (es) 2021-09-24
EP3858859A1 (en) 2021-08-04
US20170037132A1 (en) 2017-02-09
US10544224B2 (en) 2020-01-28
US20200190198A1 (en) 2020-06-18
HUE053966T2 (hu) 2021-08-30
JP2023024973A (ja) 2023-02-21
WO2017011666A1 (en) 2017-01-19
SI3322731T1 (sl) 2021-03-31
PL3322731T3 (pl) 2021-05-31
CN107922502A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
HRP20210399T1 (hr) Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1)
JP2018522887A5 (hr)
HRP20210440T1 (hr) Kombinirana terapija za rak
HRP20231156T1 (hr) Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
KR102333658B1 (ko) 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
HRP20192285T1 (hr) Anti-ox40 protutijela i postupci uporabe
RU2016148927A (ru) Лечение рака легкого с помощью комбинации антитела против pd-1 и другого противоракового средства
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2020008445A (es) Metodos para tratar el cancer con anticuerpos anti-pd-1.
RU2017117664A (ru) Комбинация
EA201792273A1 (ru) Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
JP2017537090A5 (hr)
MY196756A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
US11230598B2 (en) Antibodies and methods for depleting regulatory bio cells and use in combination with immune checkpoint inhibitors
MX2020008446A (es) Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
IL278423B2 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
JP2018500332A5 (hr)
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
RU2017105118A (ru) Нейтрализация ингибирующих путей в лимфоцитах
EP3572430A3 (en) Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
MX2024000780A (es) Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon.
MA44560B1 (fr) Anticorps anti-cd38 spécifiques pour le traitement de cancers humains
JP2019503387A5 (hr)